Imcivree (Setmelanotide) Becomes 1st Treatment Approved in US for 3 Rare Obesity Disorders

Top-line results from 21 participants showed that Imcivree resulted in at least a 10% weight loss in 80% of POMC/PCSK1 deficiency patients and in ...

from Google Alert - How to lose weight https://ift.tt/2JqBOHV